Sickle cell trait

Overview

Sickle cell trait represents a carrier state for sickle cell disease, a serious inherited blood disorder. Individuals with the trait possess one pathogenic variant in HBB and one functioning copy, which means they produce both typical haemoglobin A and variant haemoglobin S. This combination generally provides sufficient normal haemoglobin for red blood cells to function properly, and most carriers experience no health complications related to their carrier status throughout their lives.

The trait is particularly common in populations with ancestral origins in regions where malaria has been endemic, including sub-Saharan Africa, the Mediterranean, Middle East, and parts of India. In these populations, carrying one sickle cell variant historically offered survival advantage against severe malaria. Within the UK, approximately 8% of individuals with African or African-Caribbean heritage carry the trait, though it occurs across diverse ethnic backgrounds. Carrier status is primarily relevant for family planning, as two carriers have a one-in-four chance with each pregnancy of having a child with sickle cell disease.

The NHS Sickle Cell and Thalassaemia Screening Programme offers testing to all pregnant women and their partners, as well as to newborn babies through the newborn blood spot screening programme. Identifying carriers allows families to access genetic counselling and make informed reproductive choices, whilst also helping healthcare professionals provide appropriate guidance when carriers face situations that might rarely trigger symptoms.

Symptoms & clinical features

The vast majority of people with sickle cell trait remain completely asymptomatic throughout their lives and have normal life expectancy. The single functioning copy of HBB typically produces adequate amounts of normal haemoglobin A, meaning red blood cells maintain their usual disc shape and flexibility under ordinary circumstances. Routine blood counts, physical examinations, and general health markers are indistinguishable from those without the trait in most carriers.

Rarely, symptoms may emerge under extreme physiological conditions that create severe hypoxia (very low oxygen levels), dehydration, or both. These situations might include unpressurised exposure to very high altitudes, extremely intense physical exertion in hot conditions without adequate hydration, or certain medical procedures. Under such circumstances, the haemoglobin S molecules may cause some red blood cells to adopt an abnormal shape, potentially leading to complications such as exercise-related muscle breakdown, blood in urine following strenuous activity, or very rarely splenic complications. However, these events remain uncommon, and most carriers participate fully in physical activities, including competitive sports, without difficulty.

Carriers should be aware of their status when planning activities such as scuba diving or travel to high altitudes, as simple precautions like maintaining excellent hydration and allowing proper acclimatisation can further minimise any theoretical risks. Healthcare providers may also consider carrier status when planning certain surgical procedures to ensure appropriate perioperative care, though again, complications remain exceptionally uncommon.

Video: Genetics 101

Affected organs

Sickle cell trait primarily relates to red blood cells, which carry oxygen from the lungs to tissues throughout the body. The variant haemoglobin S differs from typical haemoglobin A in structure, but this alteration generally causes no functional impairment when sufficient haemoglobin A is present. Red blood cells in carriers maintain normal shape, flexibility, and lifespan under usual conditions, meaning oxygen delivery to organs and tissues proceeds normally.

In the rare situations where symptoms do occur, the kidneys represent the organ system most commonly affected in carriers. Some research suggests that carriers may have a slightly increased likelihood of blood in the urine following intense exercise or of developing certain kidney conditions over a lifetime, though absolute risks remain low and most carriers maintain normal kidney function throughout life. The spleen, which filters blood and removes damaged red blood cells, may very rarely be affected during extreme altitude exposure or severe hypoxia, though such events are uncommon enough that routine monitoring is not recommended for asymptomatic carriers.

Blood & bone marrow

Haematological involvement

Cellular impact

Mechanism at cellular level

Risks & severity

For the overwhelming majority of carriers, sickle cell trait poses no health risks and requires no medical intervention or ongoing monitoring. Life expectancy, overall health outcomes, and quality of life parallel those of individuals without the trait. The primary significance of carrier status relates to reproductive risks rather than personal health risks, as two carriers together face a 25% chance with each pregnancy of having a child affected by sickle cell disease, a condition requiring lifelong specialist haematology care.

The rare situations where carriers might experience symptoms typically involve extreme environmental or physiological stresses that most people would not routinely encounter. Maintaining good hydration during intense physical activity and allowing proper acclimatisation when travelling to high altitudes represent sensible precautions. Evidence supports full participation in athletic activities for carriers, with attention to hydration and gradual conditioning. Some specialist activities such as unpressurised flight above certain altitudes or deep-sea diving may warrant discussion with occupational health advisers familiar with the specific physiological demands involved, though many carriers pursue such activities without complications when appropriate safety protocols are followed.

Genetic causes

Sickle cell trait results from inheriting one pathogenic variant in HBB, the gene providing instructions for producing beta-globin protein. This protein partners with alpha-globin to create haemoglobin, the complex molecule within red blood cells responsible for binding and transporting oxygen. A single DNA change in the gene leads to altered protein structure, creating haemoglobin S rather than typical haemoglobin A.

Carriers who possess one altered copy alongside one typical copy produce both forms of haemoglobin within their red blood cells. The presence of substantial haemoglobin A prevents the problematic polymerisation of haemoglobin S molecules that occurs in sickle cell disease, where individuals inherit two pathogenic variants and manufacture predominantly haemoglobin S. When oxygen levels remain normal, this mixed population of haemoglobin types functions effectively, maintaining red blood cell shape and flexibility.

The HBB gene is located on chromosome 11, and hundreds of different variants in this gene have been identified. Whilst the classic sickle variant remains most common, carriers may occasionally inherit other beta-globin variants. Genetic testing through the NHS can identify specific variants and clarify carrier status, particularly important for family planning and prenatal counselling.

• HBB
  hemoglobin subunit beta

Inheritance pattern

Sickle cell trait follows an autosomal recessive carrier inheritance pattern. The term autosomal indicates that the gene sits on one of the numbered chromosomes rather than the sex chromosomes, so the trait affects males and females equally. Recessive means that having one altered copy typically causes no symptoms, though the variant can be passed to children.

When both parents carry sickle cell trait, each pregnancy carries specific risks: a 25% (one in four) chance the child will inherit two pathogenic variants and have sickle cell disease, a 50% (one in two) chance the child will be a carrier like the parents, and a 25% (one in four) chance the child will inherit two typical copies and neither have the condition nor be a carrier. If only one parent is a carrier, children cannot develop sickle cell disease, though each child has a 50% chance of inheriting the variant and being a carrier themselves. Understanding these patterns helps families make informed reproductive decisions, and the NHS offers genetic counselling and prenatal testing options to couples where both partners carry the trait.

Diagnosis & testing

Identification of sickle cell trait in the UK typically occurs through the NHS Sickle Cell and Thalassaemia Screening Programme, which offers testing at two main life stages. All pregnant women are offered screening early in pregnancy, and when a mother is identified as a carrier, testing is offered to the baby's biological father. This approach allows couples where both partners carry the trait to access genetic counselling and consider prenatal diagnostic options if they wish. Additionally, all newborn babies are screened through the newborn blood spot test (heel prick test) performed when infants are five days old, which can detect both carrier status and sickle cell disease.

Laboratory diagnosis relies on haemoglobin analysis techniques that can distinguish between haemoglobin A and haemoglobin S. High-performance liquid chromatography and haemoglobin electrophoresis represent the standard methods, showing characteristic patterns in carriers who produce both types of haemoglobin. Genetic testing of HBB can confirm the specific variant present and is particularly valuable for genetic counselling, family planning, and prenatal diagnosis. Within the NHS Genomic Medicine Service, haemoglobinopathy testing follows established pathways, and clinical genetics services provide specialist input for complex cases or when prenatal diagnosis is being considered. Genetic counsellors play a vital role in explaining test results, inheritance patterns, and reproductive options to carriers and their families.

Management & lifestyle

Individuals with sickle cell trait require no routine medical interventions or specialist monitoring for their carrier status, as it does not constitute a disease requiring treatment. The focus of care centres on education, ensuring carriers understand the implications for family planning and know when to inform healthcare providers of their status. Maintaining general good health practices, including adequate hydration during physical activity and gradual acclimatisation to high altitudes, represents sensible guidance that applies to all individuals and carries particular relevance for the rare situations where carrier status might become clinically significant.

For couples where both partners carry the trait, access to genetic counselling through the NHS provides essential support for understanding reproductive risks and exploring options. These may include prenatal diagnostic testing during pregnancy or, for some families, preimplantation genetic testing in conjunction with in vitro fertilisation. Healthcare professionals in various specialties should be informed of carrier status in specific contexts, such as preoperative assessment for major surgery or when planning activities involving extreme environmental conditions. The NHS care pathway emphasises informed choice and personalised discussion rather than restrictive guidance, recognising that most carriers live full, active lives without health limitations related to their genetic status.

UK care pathway

For individuals with sickle cell trait, the NHS care pathway centres on screening, education, and genetic counselling rather than ongoing clinical management. The NHS Sickle Cell and Thalassaemia Screening Programme coordinates carrier identification through antenatal and newborn screening, with specialist haemoglobinopathy counsellors available to explain results and implications. When both partners in a couple are identified as carriers, referral to clinical genetics services provides access to detailed genetic counselling about reproductive risks and options, including prenatal diagnosis and preimplantation genetic testing for those considering these approaches.

Carriers themselves require no routine specialist follow-up or monitoring for their carrier status, as it does not constitute a disease requiring treatment. However, awareness of carrier status can be relevant in specific medical contexts, such as preoperative assessment for major surgery or when planning activities involving extreme altitude or environmental conditions. General practitioners and specialist clinicians can access guidance on managing these situations when they arise. The primary ongoing value of knowing carrier status relates to family planning and ensuring that relatives who may also be carriers have the opportunity for testing if they wish, particularly before starting their own families.

Related conditions

Sickle cell trait should be distinguished from sickle cell disease, the condition that develops when an individual inherits two pathogenic HBB variants (either two sickle variants or one sickle variant plus another beta-globin variant such as haemoglobin C or beta-thalassaemia). Sickle cell disease causes significant health complications including pain crises, anaemia, increased infection risk, and organ damage, requiring specialist lifelong haematology care - a markedly different clinical picture from the typically asymptomatic carrier state.

Other haemoglobinopathy carrier states occur in similar population groups, particularly beta-thalassaemia trait and various other haemoglobin variants. Like sickle cell trait, beta-thalassaemia trait usually causes no symptoms but carries implications for children if both parents carry variants affecting beta-globin production. Individuals may occasionally carry both sickle cell trait and another haemoglobin variant, which can sometimes produce mild symptoms even in the carrier state. Comprehensive haemoglobin analysis can identify these compound carrier states, and genetic counselling helps families understand the specific implications for their reproductive risks and any health considerations that might apply.

• Beta-thalassaemia major
  Haematology
  Shares 1 gene
• HbC disease
  Haematology
  Shares 1 gene
• Sickle cell disease
  Haematology
  Shares 1 gene

Frequently asked questions

References

1. Naik R, Lebensburger J. Sickle Cell Trait and Circulating Proteome. Clinical journal of the American Society of Nephrology : CJASN. 2023. PMID: 37783470
2. Mitchell BL. Sickle Cell Trait and Sudden Death. Sports medicine - open. 2018. PMID: 29796715
3. James CM, Jenkins GC, Stephens AD. Sickle cell trait. Medicine, science, and the law. 1989. PMID: 2747458
4. Bleyer AJ, Aloi JA. Sickle Cell Trait and Interpretation of Hemoglobin A1c Levels. JAMA. 2017. PMID: 28170462
5. Wilson S, Ellsworth P, Key NS. Pregnancy in sickle cell trait: what we do and don't know. British journal of haematology. 2020. PMID: 32064587
6. Stovitz SD, Shrier I. Sickle cell trait, exertion-related death and confounded estimates. British journal of sports medicine. 2014. PMID: 23242954
7. Mickelson PE. Sickle cell trait and the eye. Archives of internal medicine. 1977. PMID: 843143
8. SICKLE-CELL trait. British medical journal. 1952. PMID: 14896173